Valproic acid metabolizing enzymes in the CYP2C9 UGT1A6 gene polymorphism analysis of the establishment of.docVIP

 PAGE \* MERGEFORMAT 15 Valproic acid metabolizing enzymes in the CYP2C9 UGT1A6 gene polymorphism analysis of the establishment of Author: Ho Kang Zhou, Zhao Xin, Yang Li Long, Zhang Zhihua [Abstract] Objective: To study the drug-metabolizing enzyme gene polymorphism on the metabolism of valproate and the establishment of analysis of valproic acid-metabolizing enzymes CYP2C9, UGT1A6 gene polymorphism method. Methods: The whole blood drawn from human gDNA, design primer CYP2C9 and UGT1A6, and using restriction fragment length polymorphism (RFLP) technology, methods CYP2C9 * 2, CYP2C9 * 3, CYP2C9 * 4, CYP2C9 * 5, UGT1A6 * 2 and UGT1A6 * 3 sub-types. Results: The successful design of the primers used for amplification with CYP2C9 * 3, CYP2C9 * 4, CYP2C9 * 5 fragment, and sequenced verified. Conclusion: A simple and reliable RFLP genotyping method. [Keywords:] sodium valproate; drug-metabolizing enzyme; gene; polymorphism [Abstract] Objective: In order to study the effect of drug  metabolizing enzymes (DME) polymorphism on the metabolism of valproic acid (VPA), we set up a method to analyze the DME gene polymorphism. Methods: The GDNA were extracted from blood of human. The CYP2C9 and UGT1A6 gene were amplified with PCR. We used the restriction fragment length polymorphism (RFLP) to classify the CYP2C9 * 2, CYP2C9 * 3, CYP2C9 * 4, CYP2C9 * 5, UGT1A6 * 2 and UGT1A6 * 3 genotypes . Results: A successful design of the primers was used to contain expansion of CYP2C9 * 3, CYP2C9 * 4, CYP2C9 * 5 of the clips, and sequencing and verification were performed.Conclusions: We established a simple and reliable RFLP method to group the UGT1A6 and CYP2C9. [Keywords:] Valproic acid; Drug  metabolizing enzymes; Gene; Polymorphism Sodium valproate (VPA) is a common treatment of children with epilepsy drugs, the effective therapeutic concentration of 50 ~ 100 μ g / mL, but a great individual differences, taking the same dose after the blood concentration monitoring, can be